• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    PMI U.S. Calls for Science‑Based Policy and Credible, Open Dialogue to Accelerate America's Smoke‑Free Future

    4/17/26 8:00:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $PM alert in real time by email

    WASHINGTON, April 17, 2026 /PRNewswire/ -- Philip Morris International's U.S. businesses (PMI U.S.) brought a pointed message to Washington this week: America's transition away from combustible cigarettes is being held back—not by a lack of science, but by a lack of urgency. The call comes on the heels of Technovation, PMI's global science and innovation summit held in Washington, D.C., where policymakers, scientists, business leaders, public health advocates and the media examined the persistent challenges of cigarette smoking and the urgent need for evidence-based solutions. Central to those discussions: new research in the U.S. showing that a fundamental misperception among American legal-age adult smokers is actively slowing progress.

    Philip Morris International U.S. (PRNewsfoto/PMI US Corporate Services, Inc.)

    The findings of a PMI U.S. commissioned nationwide survey conducted by Povaddo LLC underscore the challenge: Seventy-three percent believe all tobacco and nicotine products carry the same risk, a misconception that can discourage those who continue to smoke from exploring FDA-authorized smoke-free alternatives. While the majority of Americans want to see more done to reduce smoking-related harm, progress has stalled. PMI U.S. says these findings point to a credibility crisis in public discourse around smoking and harm reduction, one that is costing lives.

    Members of the Congressional Tobacco Harm Reduction Caucus echoed this urgency at Technovation, emphasizing the need for public health regulation that keeps pace with science and innovation. "We owe it to the American people to have better health outcomes," one caucus panelist said, underscoring bipartisan support for policies that reflect the latest evidence—not outdated assumptions.

    "The data are clear: When adults who smoke aren't aware that better options exist, they are more likely to keep smoking. For those who would otherwise continue using combustible cigarettes, science-backed smoke-free alternatives represent a better choice, and public health policy should support informed choice and responsible progress," said Stacey Kennedy, Chief Executive Officer of PMI U.S. "If we are serious about reducing the harm caused by smoking in the United States, we need policies and conversations rooted in science, not stigma."

    At Technovation, PMI U.S. outlined several core positions: 

    • Science-based, smoke-free alternatives represent a better choice for adults who would otherwise continue to smoke. 
    • Despite recent progress, there remains a backlog of smoke-free product applications at the U.S. Food and Drug Administration (FDA). Adults who smoke deserve access to the science-based, smoke-free options still awaiting agency review. 
    • Misperceptions about nicotine and the role of combustion in smoking-related disease impede progress. Public and medical understanding of the science behind tobacco harm reduction is essential—and long overdue.
    • To accelerate progress, the FDA should clearly communicate, especially to medical professionals, what the science says about smoke-free products' relative risk profiles, so adults who smoke can make informed choices.
    • Collaboration among government, public health experts, scientists, and industry is needed to accelerate America's transition away from cigarettes, while protecting youth and supporting informed adult choice. 

    These themes are explored further in PMI U.S.'s "Forgotten Smoker" white paper, which examines the 25-30 million adult Americans who continue to smoke and highlights the need for better access to affordable, smoke-free options and more accurate information about the continuum of risk.

    Videos from Technovation are available at: https://www.pmi.com/technovation2026presskit/.

    PMI U.S.: Invested in America

    Philip Morris International Inc.'s U.S. businesses are invested in America's future and advancing a smoke-free nation. The businesses are committed to providing the 25-30 million legal-age consumers who smoke cigarettes with better, smoke-free alternatives and to ensuring the products are marketed responsibly. From PMI's global headquarters in Stamford, Connecticut, and other locations nationwide, PMI U.S. contributes leadership, jobs, investment, and innovation in the U.S. The U.S. businesses employ more than 3,000 people across America and operate product manufacturing facilities, including in Owensboro, Kentucky, and Wilson, North Carolina. For more information, please visit www.uspmi.com.

    References to "PMI" mean the Philip Morris International family of companies. "PMI U.S.," "we," "our," and "us" refer to one or more PMI U.S. businesses.

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/pmi-us-calls-for-sciencebased-policy-and-credible-open-dialogue-to-accelerate-americas-smokefree-future-302745877.html

    SOURCE PMI US Corporate Services, Inc.

    Get the next $PM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PM

    DatePrice TargetRatingAnalyst
    1/20/2026$180.00Buy → Hold
    Jefferies
    7/9/2025$220.00Buy
    Jefferies
    5/22/2025$195.00Buy
    Needham
    4/25/2025$170.00Sell → Neutral
    UBS
    3/14/2025Hold → Buy
    Argus
    1/16/2025$140.00Overweight
    Morgan Stanley
    3/5/2024Buy → Hold
    Argus
    2/13/2024Sell → Hold
    Societe Generale
    More analyst ratings

    $PM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PMI U.S. Calls for Science‑Based Policy and Credible, Open Dialogue to Accelerate America's Smoke‑Free Future

    WASHINGTON, April 17, 2026 /PRNewswire/ -- Philip Morris International's U.S. businesses (PMI U.S.) brought a pointed message to Washington this week: America's transition away from combustible cigarettes is being held back—not by a lack of science, but by a lack of urgency. The call comes on the heels of Technovation, PMI's global science and innovation summit held in Washington, D.C., where policymakers, scientists, business leaders, public health advocates and the media examined the persistent challenges of cigarette smoking and the urgent need for evidence-based solutions. Central to those discussions: new research in the U.S. showing that a fundamental misperception among American legal

    4/17/26 8:00:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    One in Three Cigarettes in the Region of The Americas in 2025 Is Illicit, New Study Finds

    A new report highlights that 31.9% of cigarettes consumed in the Latin America and Canada region are from the illicit market, making it a global hotspot for illicit cigarette consumption, according to Philip Morris International internal estimates and other third-party reports. An estimated 77 billion illicit cigarettes were consumed in 2025 across the 11 countries analyzed in the study, resulting in an estimated USD 8.5 billion in lost tax revenues during the year. Philip Morris International (NYSE:PM) today emphasizes the importance of effective policymaking in responding to the growing illicit tobacco trade in the Region of the Americas (excluding the United States), where almost

    4/15/26 8:00:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International to Host Webcast of 2026 First-Quarter Results

    Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) will host a live audio webcast on Wednesday, April 22, 2026, at 9:00 a.m. ET, to discuss its 2026 First-Quarter financial results, which will be issued at approximately 7:00 a.m. ET the same day. The webcast can be accessed here. The webcast will be hosted by Emmanuel Babeau, Group Chief Financial Officer, and will include discussion of PMI's financial results and a Q&A session with the investment community. The webcast will be in a listen-only mode. The webcast may also be accessed on mobile devices by downloading PMI's Investor Relations App at www.pmi.com/irapp. The webcast recording and the slides and script will

    4/15/26 7:59:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Philip Morris International downgraded by Jefferies with a new price target

    Jefferies downgraded Philip Morris International from Buy to Hold and set a new price target of $180.00

    1/20/26 9:10:49 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Jefferies resumed coverage on Philip Morris International with a new price target

    Jefferies resumed coverage of Philip Morris International with a rating of Buy and set a new price target of $220.00

    7/9/25 8:31:10 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Needham initiated coverage on Philip Morris International with a new price target

    Needham initiated coverage of Philip Morris International with a rating of Buy and set a new price target of $195.00

    5/22/25 8:27:06 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Group Controller Dobrowolski Reginaldo covered exercise/tax liability with 22 shares (SEC Form 4)

    4 - Philip Morris International Inc. (0001413329) (Issuer)

    3/9/26 4:23:03 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Group Chief Financial Officer Babeau Emmanuel covered exercise/tax liability with 2,228 shares and sold $6,138,418 worth of shares (33,800 units at $181.61), decreasing direct ownership by 18% to 164,463 units (SEC Form 4)

    4 - Philip Morris International Inc. (0001413329) (Issuer)

    2/20/26 4:01:45 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Group Controller Dobrowolski Reginaldo covered exercise/tax liability with 250 shares and sold $1,100,880 worth of shares (6,000 units at $183.48), decreasing direct ownership by 20% to 21,182 units (SEC Form 4)

    4 - Philip Morris International Inc. (0001413329) (Issuer)

    2/20/26 4:01:38 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    SEC Filings

    View All

    SEC Form DEFA14A filed by Philip Morris International Inc

    DEFA14A - Philip Morris International Inc. (0001413329) (Filer)

    3/31/26 2:03:06 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Philip Morris International Inc

    SCHEDULE 13G/A - Philip Morris International Inc. (0001413329) (Subject)

    3/27/26 11:22:44 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form DEFA14A filed by Philip Morris International Inc

    DEFA14A - Philip Morris International Inc. (0001413329) (Filer)

    3/26/26 6:06:32 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Financials

    Live finance-specific insights

    View All

    Philip Morris International Declares Regular Quarterly Dividend of $1.47 Per Share

    Regulatory News: The Board of Directors of Philip Morris International Inc. (NYSE:PM) today declared a regular quarterly dividend of $1.47 per common share, payable on April 13, 2026, to shareholders of record as of March 19, 2026. The ex-dividend date is March 19, 2026. For more details on stock, dividends and other information, see www.pmi.com/dividend. Philip Morris International: A Global Smoke-Free Champion Philip Morris International is a leading international consumer goods company, actively delivering a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company's current product portfolio primarily

    3/5/26 7:00:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International Presents at 2026 CAGNY Conference; Reaffirms 2026 Full-Year Forecast

    Regulatory News: Philip Morris International Inc.'s (PMI) (NYSE:PM) Group CEO PMI, Jacek Olczak, and Group Chief Financial Officer, Emmanuel Babeau, will address investors today at the 2026 Consumer Analyst Group of New York (CAGNY) Conference at approximately 10:00 a.m. ET. The live webcast and presentation slides will be available here. The webcast replay will be available at the same link for six months after the event. The webcast may also be accessed on mobile devices by downloading PMI's Investor Relations App at www.pmi.com/irapp. The presentation will cover: How a transformed PMI is leading the industry in an evolving operating environment; The success and future opportu

    2/18/26 7:00:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International Reports 2025 Fourth-Quarter & Full-Year Results

    Delivers Full Year 2025 Reported Diluted EPS of $7.26 compared to $4.52 in 2024 and Adjusted Diluted EPS of $7.54, Representing Growth of 14.8%, and 14.2% on a Currency-Neutral Basis; Provides 2026 - 2028 Growth Targets Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) today announces its 2025 fourth quarter results.1 "We achieved another remarkable year of results in 2025, with a fifth consecutive year of volume growth, net revenues surpassing $40 billion, including close to $17 billion from our smoke-free business, and very good operating margin expansion," said Jacek Olczak, Group CEO PMI. "With excellent results in 2024 and 2025, we have delivered our three-year CA

    2/6/26 6:59:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Philip Morris International Inc (Amendment)

    SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)

    2/9/24 6:21:26 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Philip Morris International Inc (Amendment)

    SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)

    2/9/24 6:05:54 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Philip Morris International Inc (Amendment)

    SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)

    1/29/24 3:26:29 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Leadership Updates

    Live Leadership Updates

    View All

    Philip Morris International Opens Dialogue on the Future of Human Cognition as a Defining Frontier in the Age of AI

    The paper calls for global debate to ensure AI enhances—rather than diminishes—uniquely human strengths in an increasingly automated world Philip Morris International Inc. (NYSE:PM) today released a new white paper, "Human Cognition: The Next Frontier?", inviting leaders across business, policy, and academia to join a global conversation on the evolving role of human cognition as artificial intelligence transforms work, society, and the economy. The white paper explores how human capabilities such as - critical thinking, creativity and adaptability - are poised to become the "superskill" of the future, driving progress in an era of human-machine collaboration. As AI automates routine ta

    1/20/26 5:03:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Molex, a Parent to Phillips Medisize, Announces Agreement to Acquire the Vectura Group Limited, Expanding Its Drug Delivery Capabilities in Inhalation

    Pharmaceutical customers and patients to benefit from the combined design, development and manufacturing services of Vectura and Phillips Medisize Phillips Medisize to add a market-leading position in inhalation combination product development to its existing suite of drug delivery device design capabilities Vectura employees to join a large global company, dedicated to improving patients' lives through innovative products and world class quality and manufacturing capabilities Molex, a parent to Phillips Medisize, a leader in the design, engineering and manufacturing of pharmaceutical drug delivery, in vitro diagnostic and medtech devices, announced that, through its affiliate Molex

    9/17/24 9:11:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International Names New External Affairs Leader

    Philip Morris International Inc. (PMI) (NYSE:PM) is pleased to announce the appointment of Christos Harpantidis to the position of Senior Vice President, External Affairs effective May 1, 2024. In his new role, Mr. Harpantidis will report to the company's CEO, Jacek Olczak. "Christos is an experienced business leader with a proven track record of engaging society on the benefits of tobacco harm reduction and risk-proportionate regulation for smoke-free products," said CEO Jacek Olczak. "He has been instrumental in building our smoke-free business in Greece and the South East Europe Area as we evolve away from cigarettes. I'm looking forward to working with Christos and excited to see what

    3/26/24 5:48:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care